CEL SCI Corp (CVM) stock
CVMNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
$1.19−0.12 (-9.16%)
Close on Nov 12, 2026Market cap $20.93MP/E –Yield –
Cel Sci cash
Cash and short-term investments held at the end of each period.
Cel Sci's cash was $6.53M at Jun 30, 2026. For fiscal 2025 it was $10.95M, up 131.2% from the year before. Over ten years it grew 6.7% a year on average. The highest annual figure on record is $42.21M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $10.95M | +131.2% |
| FY2024 | Sep 30, 2024 | $4.74M | +14.3% |
| FY2023 | Sep 30, 2023 | $4.15M | -81.7% |
| FY2022 | Sep 30, 2022 | $22.67M | -46.3% |
| FY2021 | Sep 30, 2021 | $42.21M | +172.2% |
| FY2020 | Sep 30, 2020 | $15.51M | +83.7% |
| FY2019 | Sep 30, 2019 | $8.44M | -18.1% |
| FY2018 | Sep 30, 2018 | $10.31M | +335.1% |
| FY2017 | Sep 30, 2017 | $2.37M | -18.8% |
| FY2016 | Sep 30, 2016 | $2.92M | -49.0% |
| FY2015 | Sep 30, 2015 | $5.73M | -32.7% |
| FY2014 | Sep 30, 2014 | $8.51M | +20359.5% |
| FY2013 | Sep 30, 2013 | $41.61K | -98.9% |
| FY2012 | Sep 30, 2012 | $3.94M | -7.5% |
| FY2011 | Sep 30, 2011 | $4.26M | -84.0% |
| FY2010 | Sep 30, 2010 | $26.57M | -20.9% |
| FY2009 | Sep 30, 2009 | $33.57M | +4619.5% |
| FY2008 | Sep 30, 2008 | $711.26K | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $6.53M | +264.1% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $1.89M | -1.7% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $6.28M | +36.1% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $10.95M | +131.2% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $1.79M | +366.1% |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $1.92M | -63.8% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $4.61M | +42.3% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $4.74M | +14.3% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $384.65K | -92.5% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $5.31M | -47.2% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $3.24M | -82.0% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $4.15M | -81.7% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $5.14M | -81.7% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $10.05M | -70.7% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $18.02M | -51.4% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $22.67M | -46.3% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $28.07M | -40.4% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $34.28M | +95.0% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $37.11M | +69.8% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $42.21M | +172.2% |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $47.11M | +133.9% |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $17.58M | +22.7% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $21.86M | +133.0% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | $15.51M | +83.7% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $20.14M | +112.3% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $14.33M | +159.9% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $9.38M | +40.4% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $8.44M | -18.1% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $9.49M | +304.2% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $5.51M | +80.1% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $6.68M | +211.9% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $10.31M | +335.1% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $2.35M | +90.4% |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $3.06M | +100.2% |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $2.14M | -10.2% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $2.37M | -18.8% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $1.23M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $1.53M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $2.39M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $2.92M | – |
See a number that looks wrong?